News | Cath Lab | January 08, 2016

Seeking Treatment Earlier May Improve Heart Attack Outcomes

Restoring blood flow quickly after heart attack symptoms begin key to less heart damage

heart attack outcomes, door-to-ballon time, symptoms, JACC Cardiovascular Interventions, PCI

January 8, 2016 — A new study published online in JACC: Cardiovascular Interventions reveals that delays in recognizing symptoms of heart attack patients and seeking treatment are associated with increased damage to the heart.

Door-to-balloon time is the time from when a heart attack patient arrives in the emergency room until percutaneous coronary intervention (PCI) is performed to restore blood flow. American College of Cardiology/American Heart Association (ACC/AHA) guidelines state that hospitals treating ST-segment elevation myocardial infarction (STEMI) patients with emergency PCI should do so within 90 minutes or less of reaching the hospital. The ACC launched the Door-to-Balloon (D2B) Alliance in 2006 to reduce the time to which STEMI patients receive PCI in U.S. hospitals.

According to the study, in about 90 percent of PCI cases blood flow is restored in the surface of the heart, but in about one-third of patients, blood flow is not restored to the heart muscle. Researchers in this study compared the impact of the time from heart attack symptom onset-to-balloon and door-to-balloon on heart muscle function.

Researchers reviewed the records of 2,056 patients in the multi-center Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial comparing patients with symptom onset-to-balloon time in three categories: two hours and less; more than two hours to four hours; and more than four hours.

Patients who took a total of two to four hours or longer to get treated with a balloon angioplasty were less likely to have blood flow fully restored and were more likely to die within three years than patients treated more quickly.

“The decrease in median door-to-balloon time in recent years has not resulted in a reduction in mortality in STEMI patients,” said Roxana Mehran, M.D., a study author and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine. “This study highlights the need to reconsider the role of door-to-balloon as a performance metric and examine the utility of a broader metric of systems delay such as first medical contact to balloon time as well as total ischemic time.”

In an accompanying editorial, Michael A. Kutcher, M.D., of Wake Forest Baptist Medical Center, said the door-to-balloon metric and systems in place are extremely valuable and should continue; however, physicians need to pay attention to associated metrics such as the symptoms and signs of the onset of ischemia, which is loss of blood flow. He attributed the lack of significant improvement in mortality and morbidity with reduced door-to-balloon time to the fact that microvascular damage can still occur with shorter door to balloon times and can lead to increased risk of death.

“Patients with prolonged symptom onset-to-balloon time are a high-risk group and should be treated accordingly with assertive strategies,” Kutcher said. “We as an interventional cardiology community should continue to educate the public and health care providers regarding the importance to quantify symptom onset-to-balloon time and follow through with prompt action.”

For more information: www.interventions.onlinejacc.org

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init